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Abstract
Background Pancreatic cancer is often accompanied by cachexia, a syndrome of severe weight loss and muscle wasting. A
suboptimal response to nutritional support may further aggravate cachexia, yet the inﬂuence of nutrition on protein kinetics
in cachectic patients is poorly understood.
Methods Eight cachectic pancreatic cancer patients and seven control patients received a primed continuous intravenous
infusion of L-[ring-2H5]phenylalanine and L-[3,3-
2H2]tyrosine for 8 h and ingested sips of water with L-[1-
13C]phenylalanine
every 30min. After 4 h, oral feeding was started. Whole body protein breakdown, protein synthesis, and net protein balance
were calculated. Results are given as median with interquartile range.
Results Baseline protein breakdown and protein synthesis were higher in cachectic patients compared with the controls
(breakdown: 67.1 (48.1–79.6) vs. 45.8 (42.6–46.3)μmol/kg lean body mass/h, P = 0.049; and synthesis: 63.0 (44.3–75.6) vs.
41.8 (37.6–42.5)μmol/kg lean body mass/h, P = 0.021). During feeding, protein breakdown decreased signiﬁcantly to 45.5
(26.9–51.1)μmol/kg lean body mass/h (P = 0.012) in the cachexia group and to 33.7 (17.4–37.1)μmol/kg lean body mass/h
(P = 0.018) in the control group. Protein synthesis was not affected by feeding in cachectic patients: 58.4 (46.5–76.1)μmol/kg
lean body mass/h, but was stimulated in controls: 47.9 (41.8–56.7)μmol/kg lean body mass/h (P = 0.018). Both groups showed
a comparable positive net protein balance during feeding: cachexia: 19.7 (13.1–23.7) and control: 16.3 (13.6–25.4)μmol/kg lean
body mass/h (P = 0.908).
Conclusion Cachectic pancreatic cancer patients have a higher basal protein turnover. Both cachectic patients and controls
show a comparable protein anabolism during feeding, albeit through a different pattern of protein kinetics. In cachectic
patients, this is primarily related to reduced protein breakdown, whereas in controls, both protein breakdown and protein
synthesis alterations are involved.
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Background
Pancreatic cancer is the eighth leading cause of cancer deaths in
men and the ninth in women with 138100 and 127900 annual
deaths worldwide, respectively.1 Cancer cachexia, a complex
syndrome characterized by weight loss and muscle wasting, is
a major problem of pancreatic cancer and greatly decreases sur-
vival and quality of life.2,3 It is responsible for more than 80% of
pancreatic cancer related deaths.4 The exact pathogenesis of
cancer cachexia is not fully understood, but systemic
OR IG INAL ART ICLE
© 2015 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society of Sarcopenia, Cachexia and Wasting Disorders
Journal of Cachexia, Sarcopenia and Muscle 2015; 6: 212–221
Published online 20 April 2015 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/jcsm.12029
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium,
provided the original work is properly cited, the use is non-commercial and no modiﬁcations or adaptations are made.
inﬂammation, a negative energy balance, malabsorption, and
anorexia play an important role.5 Metabolic changes are most
profound in protein metabolism, peripheral tissues furnishing
nitrogenous and carbon substrate to sustain the acute phase
response, and tumour growth. This leads to net negative periph-
eral protein metabolism, presenting as muscle wasting.
A key feature of cancer cachexia is that it cannot be fully
reversed by regularly used nutritional support.3,5 This lack of
response indicates that nutrient handling and especially protein
metabolism are altered in cachectic patients. This might be due
to a failing anabolic response (anabolic resistance), increased
breakdown, or a reprioritisation of nitrogen economy away from
peripheral tissues (muscle) towards increased hepatic produc-
tion of acute phase proteins.6–9 The latter theory was studied
previously by our group in cachectic pancreatic cancer patients
with an acute phase response.2,10 We found normal albumin11
but increased ﬁbrinogen synthesis rates12 in fasted cachectic
pancreatic cancer patients. Moreover, feeding in such patients
was associated with a marked increase in ﬁbrinogen synthesis,13
supporting the theory of reprioritisation. However, the mecha-
nisms involved remain unclear, and studies providing information
on whole body protein synthesis and breakdown and their
response on feeding in cachectic cancer patients are lacking.
This study aimed to investigate the effect of protein meal
feeding on whole body protein turnover, protein synthesis,
and protein breakdown in cachectic pancreatic cancer
patients compared with non-oncologic surgical control
patients by using established methods of primed continuous
infusions of stable isotope-labelled amino acids.
Materials and methods
Subjects
To investigate the effect of enteral feeding on protein metabo-
lism in cancer cachexia, cachectic patients with pancreatic head
cancer were studied. Inclusion criteria were unresectable
biopsy-proven, primary or recurrent pancreatic cancer, and
cachexia. Cancer cachexia was deﬁned as weight loss of
>5% in 6months, according to international consensus.5
Age-matched and sex-matched weight-stable patients admit-
ted for surgery for benign disease (cholecystectomy or ingui-
nal hernia repair) were included as a control group. Exclusion
criteria for both groups were radiotherapy or chemotherapy,
surgery in the month preceding the study, endocrine or
metabolic disorders, fever, anaemia, and steroid use. Height,
bodyweight, bodyweight loss, triceps skinfold thickness, mid-
arm muscle circumference, and handgrip strength were mea-
sured on admission. Body weight loss was estimated by
subtracting current measured body weight from reported
normal body weight 6months ago. For handgrip strength,
the highest grip strength was recorded after measuring three
times for both hands. Laboratory measurements that were
taken at admission as part of standard care were recorded.
Body composition was assessed by multiple frequency bio-
electrical impedance measurements at 5 and 200 kHz with
either a four terminal RJL BIA 101 (RJL Systems, Detroit,
USA) or the Bodystat Dualscan 2005 (Bodystat Ltd., UK).14
Since the study protocol is demanding, especially for severely
ill patients, a sample size of eight cachectic patients and
seven control patients was chosen. This sample size was
proven by our research group to provide adequate (patho)
physiological data in tracer studies in the past.13,15
Study protocol
Patients and healthy subjects were studied after an overnight
fast. Starting at 8 a.m., two cannulas were inserted: one into
the antecubital vein for stable isotope infusion and one into
the dorsal hand vein in the contralateral arm for arterialized
blood sampling using a custom made heated box (50°C, J.
Cambell and Dr. H. Brash, Department of Medical Physics, Royal
Inﬁrmary of Edinburgh). After a baseline blood sample had been
taken for measurement of background isotope enrichment and
C-Reactive-Protein (CRP), patients received a priming dose of
L-[1-13C]phenylalanine (2.3μmol/kg), L-[ring-2H5]phenylalanine
(2.2μmol/kg), L-[3,3-2H2]tyrosine (0.9μmol/kg), and L-
[ring-2H4]tyrosine (0.3μmol/kg) followed by a continuous intra-
venous infusion of L-[ring-2H5]phenylalanine (3.5μmol/kg/h)
and L-[3,3-2H2]tyrosine (1.3μmol/kg/h). Patients also received
a primed continuous infusion of L-[2H8]phenylalanine for a
separate research question not discussed in this paper. Subse-
quent arterialized blood samples were drawn hourly. For the
ﬁrst 4 h of the study, subjects drank 60ml of water mixed with
L-[1-13C]phenylalanine every 30min to obtain a steady ‘infusion
rate’ of 3.5μmol/kg/h. Thereafter, subjects started drinking
a commercially available sip feeding (Fortisip, Nutricia Ltd,
Wiltshire, UK) mixed with L-[1-13C]phenylalanine at a rate of
60ml per 30min for another 4h. Macronutrient composition of
the sip feed was protein 50 g/L (casein), carbohydrate 180g/L,
and fat 65g/L. The amino acid composition was alanine 1.7g/L, ar-
ginine 2.0g/L, aspartic acid 3.9g/L, cysteine 0.15g/L, glutamine
12.5g/L, glycine 1.0g/L, histidine 1.6g/L, isoleucine 2.85g/L, leu-
cine 5.25g/L, lysine 5.1g/L, methionine 1.65g/L, phenylalanine
2.8g/L, proline 5.0g/L, serine 3.3g/L, threonine 2.45g/L, trypto-
phan 0.7g/L, tyrosine 3.05g/L, and valine 3.6g/L. The protocol
was approved by the Lothian Research Ethical Committee of the
Local Health Board in Edinburgh. Written informed consent was
obtained from all patients.
Plasma analyses
For serum CRP, blood was collected in serum-gel clotting
tubes and centrifuged for 5min at 2500 rpm at 5°C. Aliquots
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of supernatant were frozen in liquid nitrogen and stored at
70°C until analysis. CRP was measured by ﬂuorescent polar-
ization immunoassay using an Abbott TDX analyzer and
Abbott reagents (Abbott Laboratories, Maidenhead, UK) with
a limit of detection of 1mg/L. Samples for plasma amino acid
measurements were collected in pre-chilled lithium-heparin
tubes, transported to the laboratory on ice, and centrifuged
for 5min at 2500 rpm at 5°C. Plasma proteins were precipi-
tated using 5% sulfosalicylic acid. The samples were then
frozen in liquid nitrogen and stored at 70°C until analysis.
Plasma amino acids were measured by routine high-
performance liquid chromatography techniques as described
previously.16 Plasma enrichments of L-[1-13C]phenylalanine,
L-[ring-2H5]phenylalanine, L-[3,3-
2H2]tyrosine, and L-[ring-
2H4]-
tyrosine were determined by liquid chromatography–mass
spectrometry (LC–MS).17 During transamination in vivo, L-[2H8]
phenylalanine exchanges the hydrogen atom at C2 position
with body water, forming L-[2H7]phenylalanine.
18 During ioniza-
tion in the LC–MS, L-[2H8]phenylalanine exchanges with
unlabelled phenylalanine, giving rise to some L-[2H1]phenylala-
nine. This interfered with the analysis of L-[1-13C]phenylalanine,
causing overestimation of the M+1/M ratio, and the used
LC–MS method was not able to distinguish the contribution
of the 1-13C and the 2H1. However, because of the isotopic
distribution of both tracers, L-[1-13C]phenylalanine will also
generate a sufﬁcient increase of the M+2 mass, while the
2H1 will only generate a very small amount. We therefore
used the M+2/M ratio to back calculate the M+1/M ratio,
caused by L-[1-13C]phenylalanine. Alanine transaminase,
gamma-glutamyl transpeptidase, alkaline phosphatase, and
bilirubin levels were analysed as part of standard hospital
care in the Department of Clinical Chemistry of the Royal
Inﬁrmary of Edinburgh, Scotland, according to hospital
protocols.
Calculations
All data concerning amino acid metabolism were corrected
for lean body mass. In the post-absorptive state, protein
breakdown is the only source of essential amino acids. The
plasma rate of appearance of essential amino acids, such as
phenylalanine, can therefore be used as an index of protein
breakdown. Phenylalanine and tyrosine kinetics were calcu-
lated according to the approach of Tessari et al.19 The rate
of appearance of phenylalanine (RaPHE) was calculated from
the infusion rate of L-[ring-2H5]phenylalanine (IR2H5-PHE) and
L-[ring-2H5]phenylalanine tracer–tracee ratio (TTR) in plasma
(TTR2H5-PHE) according to the following formula:
RaPHE ¼ IR2H5-PHE=TTR2H5-PHE (1)
Phenylalanine hydroxylation (PH) was calculated from
the tyrosine plasma rate of appearance calculated from
L-[3,3-2H2]-tyrosine TTR (TTR2H2-TYR) and L-[3,3-
2H2]-tyrosine
infusion rate (IR2H2-TYR) according to Equation 1 and from
the ratio between TTR2H5-PHE and the plasma TTR of its deriv-
ative L-[ring-2H4]tyrosine (TTR2H4-TYR):
PH ¼ Ra2H2-TYRxTTR2H4-TYR=TTR2H5-PHE (2)
The rate of non-hydroxylative phenylalanine disposal
(NHPD) is an index of incorporation of phenylalanine in pro-
tein and, therefore, of protein synthesis. In steady state con-
ditions, the sum of NHPD and PH equals RaPHE. NHPD could
thus be calculated from the results of Equations 1 and 2:
Protein synthesis PSð Þ ¼ NHPD ¼ RaPHE-PH (3)
Splanchnic extraction (SPEPHE), the fraction of phenylala-
nine that is taken up by the gut and/or liver during its ﬁrst-
pass, was calculated as the ratio of RaPHE calculated with
the intravenous (RaPHE-IV) and enteral phenylalanine tracer
(RaPHE-ENT):
SPEPHE ¼ 1-RaPHE-IV=RaPHE-ENTð Þ*100% (4)
Endogenous RaPHE was used as a measure of endogenous
protein breakdown (endoPB). This was calculated as the dif-
ference between the total rate of appearance of phenylala-
nine and the exogenous, enteral phenylalanine ingestion
rate (EIRPHE), corrected for SPEPHE:
Endogenous Protein breakdown endoPBð Þ ¼ RaPHE endoð Þ
¼ RaPHE- EIRPHE * 1-SPEPHE=100ð Þð Þ (5)
The phenylalanine net balance, an index of protein bal-
ance, could be calculated from protein synthesis (NHPD,
Equation 3) and protein breakdown (endogenous RaPHE,
Equation 5):
Net protein balance NBð Þ ¼ PS-endoPB (6)
Statistics
All data are presented as median and interquartile range
(IQR). Tracer ﬂuxes are expressed in μmol/kg lean body
mass/h. Data were analysed using IBM SPSS 20 for Microsoft
Windows®. Due to the sample size and high likelihood of a
non-normal distribution, non-parametric tests were used.
Differences between groups were analysed using the
Mann–Whitney U test or Fisher’s exact test, where appropri-
ate. To analyse differences within groups at different time
points, the Wilcoxon signed-rank test and Friedman test
were used. For correlations, Spearman’s ranked correlation
coefﬁcient (rs) was used. A P-value of <0.05 was considered
signiﬁcant.
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Results
Patient characteristics
Eight cachectic pancreatic cancer patients and seven control
patients (six with gallstones and one with bilateral inguinal
hernia) were included in this study. Patient characteristics
are displayed in Table 1. Two pancreatic cancer patients had
proven liver metastasis. Groups were comparable
with respect to age, sex, height, lean body mass, and
male/female ratio. Weight, BMI, triceps skinfold thickness,
and mid-arm muscle circumference were signiﬁcantly lower
in the cachexia group. Patients did not show signs of ascites
or oedema. The percentage weight loss in the cachexia group
was very high with almost all (n = 7) cachectic patients having
more than 10% weight loss. All pancreatic cancer patients
had some degree of functional status loss but were able to
come to the hospital themselves using public transportation
or a taxi. Patients were mildly to moderately anorexic but tol-
erated the protocol well. During the last 2 h of the protocol,
some cancer patients consumed less liquid feed due to an-
orexia, resulting in a small non-signiﬁcant difference in sip
feed intake between the cachexia group and control group:
8.1 (IQR: 5.6–10.0) vs. 10.3 (IQR: 8.5–11.6)ml/kg lean body
mass protein drink corresponding with 34.2 (IQR: 23.7–42.6)
vs. 43.7 (IQR: 36.1–49.3)μmol/kg lean body mass/h phenylal-
anine (P = 0.105).
Inﬂammation and clinical chemistry
Serum CRP levels were signiﬁcantly higher in the cachectic
group compared with the controls (Table 2). Liver enzymes
(alanine transaminase, gamma-glutamyl transferase and
alkaline phosphatase) were signiﬁcantly elevated in cachectic
patients compared with controls, whereas bilirubin levels
were similarly low in both groups.
Isotopic steady state
Plasma amino acid concentrations are given in Table 2. Isoto-
pic steady state was achieved for all administered tracers
within 1 h. A new steady state equilibrium was formed again
within 1 h after the start of the oral ingestion of the sip feed
(Figure 1).
Protein breakdown (phenylalanine ﬂux) and
splanchnic extraction
At baseline, protein breakdown (RaPHE) was signiﬁcantly
higher in cachectic cancer patients compared with control pa-
tients (67.1 IQR: 48.1–79.6 vs. 45.8 IQR: 42.6–46.3μmol/kg
lean body mass/h; P = 0.049, Figure 2A). This was positively
correlated with serum CRP levels (rs = 0.658, P = 0.008). During
ingestion of the study feed, endo PB decreased signiﬁcantly to
45.5 (IQR: 26.9–51.1)μmol/kg lean body mass/h (P = 0.012) in
cancer patients and 33.7 (IQR: 17.4–37.1)μmol/kg lean body
mass/h (P = 0.018) in control subjects (Figure 2B). The magni-
tude of this decrease was not signiﬁcantly different between
both groups (P = 0.132). Splanchnic extraction was similar
between both groups during feeding (P = 0.418, Figure 2C).
Protein synthesis (non-hydroxylative phenylalanine
disposal)
Protein synthesis was higher in weight-losing cancer patients
than in controls at baseline (63.0 IQR: 44.3–75.6 vs. 41.8 IQR:
37.6–42.5μmol/kg lean body mass/h (P = 0.021, Figure 3A).
In cachectic patients, protein synthesis did not respond to
sip feeding (58.4 IQR: 46.5–76.1μmol/kg lean body mass/h;
P = 1.000), whereas protein synthesis in control patients
increased signiﬁcantly (47.9 IQR: 41.8–56.7μmol/kg lean
body mass/h; P = 0.018). Accordingly, the response of protein
Table 1 Patient characteristics
Cachectic patients Control patients
(n=8) (n=7)
P-valueb
Sex (n) Female (5) Male (3) Female (4) Male (3) 1.000
Age (yrs) 71 (20) 67 (16) 66 (12) 77 (17) 0.451
Body weight (kg) 47.6 (25.3) 53.7 (16.6) 72.3 (22.4) 77.6 (28.0) 0.003
Height (cm) 153 (13) 175 (16) 158 (5) 170 (7) 0.684
Body mass index (kg/m2) 20.3 (7.7) 19.4 (3.75) 29.0 (7.2) 26.9 (7.6) 0.005
Weight lossa (kg) 7.7 (13.4) 19.2 (19.8) — — 0.001
Weight lossa (%) 16.6 (28.3) 37.2 (40.9) — — 0.001
Lean body mass (kg) 33.7 (23.9) 46.6 (9.6) 42.8 (8.8) 56.3 (12.2) 0.132
Triceps skin fold (mm) 14.0 (3.0) 11.0 (7.0) 27.5 (11.0) 22.0 (21.0) 0.018
Mid-arm circumference (cm) 23.3 (7.0) 22.5 (3.0) 31.8 (4.0) 31.0 (7.0) 0.003
Handgrip strength (kg) 6.0 (13.0) 24.0 (1.0) 17.0 (6.0) 32.0 (13.0) 0.566
Data represent median and range
aIn 6months
bCachexia group compared with control group
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synthesis on feeding (ΔNHPD) was signiﬁcantly lower in cachec-
tic patients (0.6 IQR: 3.8 to 6.5μmol/kg lean body mass/h)
compared with control patients (9.9 IQR: 5.3–16.0μmol/kg
lean body mass/h; P=0.021). Phenylalanine hydroxylation rates
increased during feeding in the control group (4.5 IQR: 3.1–5.8
to 6.3 IQR: 4.2–7.4μmol/kg lean body mass/h; P=0.018) but
not in the cachexia group (4.1 IQR: 2.6–5.0 to 3.6 IQR: 2.8–
5.7μmol/kg lean body mass/h; P=0.779, Figure 3B).
Table 2 Laboratory results and amino acid concentrations
Cachectic patients (n=8) Control Patients (n=7) P-value
CRP (mg/L) 8.3 (4.2–31.3) 0 (0–1.8) 0.002
WBC (*109/L) 8.4 (4.6–10.5) 7.1 (4.9–8.3) 0.431
Bilirubin (μmol/L) 10.0 (8.0–18.0) 10.5 (7.8–18.5) 0.943
ALT (IU/L) 36.0 (34.0–67.0) 20.5 (14.5–30.8) 0.015
GGT (IU/L) 93.0 (47.0–168.0) 21.0 (15.8–30.5) 0.010
ALP (IU/L) 214.0 (149.0–231.0) 67.5 (60.3–101.5) 0.007
Urea (mmol/L) 4.9 (3.5–6.3) 5.2 (5.0–7.7) 0.391
Creatinine (μmol/L) 81.0 (74.0–101.0) 92.0 (82.5–106.3) 0.199
Phenylalanine (fasted, μmol/L) 44.5 (41.3–60.5) 67.0 (59.0–71.0) 0.024
Phenylalanine (fed, μmol/L) 62.5 (56.3–69.5) 84.0 (70.0–96.0) 0.009
Tyrosine (fasted, μmol/L) 50.0 (41.8–65.0) 53.0 (45.0–59.0) 0.817
Tyrosine (fed, μmol/L) 64.0 (45.0–75.0) 74.0 (55.0–90.0) 0.246
Valine (fasted, μmol/L) 124.5 (109.3–154.5) 204.0 (179.0–220.0) 0.005
Valine (fed, μmol/L) 162.0 (143.3–176.0) 252.0 (223.0–281.0) 0.001
Laboratory results and amino acid concentrations are presented as median and interquartile range. Amino acid concentrations are given
as average concentrations in the fasted (1–4 h) and fed state (5–8 h). All amino acid concentrations increased signiﬁcantly (P< 0.05)
during feeding except for Tyrosine in the cachexia group (P=0.062).
ALP, alkaline phosphatase; ALT, alanine transaminase; CRP, C-reactive protein; GGT, gamma-glutamyl transferase; WBC, white blood cells
Figure 1 Mean isotope enrichments and standard deviations of phenylalanine and tyrosine over time. Feeding was started after 4 h (arrow). Steady
states of all tracers were signiﬁcantly different during the fasted state compared with the fed state (cachexia: P = 0.019; control: P< 0.001; Friedman
test). Steady states of all tracers did not differ signiﬁcantly between groups in both fasted (1–4 h) and fed (5–8 h) states (Mann–Whitney U test).
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Protein balance
Both cachectic patients and control patients were able to
achieve a positive and comparable net protein balance during
feeding as shown in Figure 4. Net protein balance in the
cachexia group increased from 4.1 (IQR: 5.0 to 2.6) to
19.7 (IQR: 13.1–23.7)μmol/kg lean body mass/h (P = 0.012),
while in the control group, it increased from 4.5 (IQR:
5.8 to 3.1) to 16.3 (IQR: 13.6–25.4)μmol/kg lean body
mass/h (P = 0.018).
Figure 2 Whole body protein turnover, protein breakdown, and splanchnic extraction. Dots represent individual patients. (A) Whole body protein
turnover expressed as total phenylalanine rate of appearance. (B) Protein breakdown expressed as endogenous phenylalanine rate of appearance.
(C) Splanchnic extraction during feeding. Bars represent the median. There was no signiﬁcant difference in splanchnic extraction between groups.
*P< 0.05, SPE, splanchnic extraction.
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Discussion
This study has analysed the effect of sip feeding on whole
body protein turnover in cachectic pancreatic cancer
patients. It demonstrated that whole body protein turnover
is higher in cancer patients compared with that in control
patients, possibly due to inﬂammation. Although both patient
groups were able to generate a similar anabolic response to
feeding, cachectic patients were only able to achieve this by
reducing protein breakdown, whereas controls were also able
to increase protein synthesis.
Previous studies investigating protein metabolism in cancer
cachexia (gastrointestinal20 and hepatocellular carcinoma21)
found a higher whole body protein turnover compared with
healthy controls, in line with our study. In cachexia associated
with benign disease, the results are variable: whole body pro-
tein turnover was increased in patients with heart failure22
but not in tuberculosis (TBC).23 Cachectic patients with
chronic obstructive pulmonary disease (COPD) may have an
increased whole body protein turnover,24 but this is not al-
ways the case.25 These mixed results may indicate a different
pathogenesis for non-cancer cachexia compared with cancer
cachexia. Federica et al.26 did not ﬁnd an increased whole
body protein turnover in cachectic gastric cancer patients. This
could be due to the fact that they included a small group (n= 4
cancer patients) and did not correct for lean body mass. This is
important since body composition of cachectic patients differs
greatly from that of healthy individuals.3 Enteral feeding is
preferred to parenteral feeding, since this mimics the normal
situation better and generates a higher anabolic response.
Previous studies have mainly investigated the effects of total
parenteral nutrition (TPN) or parenteral amino acids and found
mixed results. Winter et al.27 found a normal anabolic
response of whole body protein turnover following
hyperaminoacidemia using intravenous amino acid infusions
in moderately cachectic non-small cell lung carcinoma
patients. Bozzetti et al.28 studied the effect of TPN on protein
synthesis and breakdown in cachectic gastric cancer patients.
Unlike our study, they found an increase in protein synthesis in
response to TPN and no change in breakdown. However, the
number of patients was very low (n = 3) and did not include
a control group.
The study by Williams et al.,29 which analysed the frac-
tional synthetic rate (FSR, protein synthesis) in the vastus
lateralis muscle of colorectal cancer patients, found that
FSR did not increase in cancer patients after the administration
of a mix of parenteral amino acids, whereas FSR increased in
matched healthy controls. Although FSR and whole body
protein synthesis are difﬁcult to compare, their general
message was in line with our results. They also found a trend
towards increased leg muscle protein breakdown in cachectic
patients that did not change after feeding. Interestingly, after
surgical removal of the tumour, the FSR increased as a result
of feeding in these patients. Only two studies have assessed
the effect of enteral feeding on protein kinetics in cachectic
patients with benign disease, but apart from the present
study, no data on the response of protein kinetics on enteral
feeding in cancer-cachexia are at hand. First, Macallan et al.
(1998)23 studied the effect of hourly feeding in cachectic
TBC patients compared with that in non-cachectic malnour-
ished and healthy controls. They found that whole body pro-
tein synthesis did not increase during feeding in cachectic
TBC patients, whereas both malnourished and healthy con-
trols showed a signiﬁcant increase, which is in line with our
results. Second, studies of Engelen et al.24 and Jonker
et al.30 studied the effect of respectively sip feeding and
bolus feeding on protein kinetics in cachectic COPD
patients. In contrast with our results, both studies found a
signiﬁcant increase in protein synthesis in COPD patients,
which was similar to the response in young healthy individ-
uals in the study of Engelen et al. There are several reasons
which may explain this difference in anabolic response.
Firstly, our study population suffered from very severe weight
loss (>10%), which could mean that their cachectic state was
more advanced than in the COPD patients resulting in a
worse anabolic response. Secondly, the COPD patients con-
sumed a drink with higher whey protein content than our
study drink. Whey protein is known to stimulate muscle pro-
tein synthesis more than other milk proteins (e.g. casein) in
elderly patients.31,32 Finally, as mentioned earlier, the more
chronic pathogenesis of COPD-related cachexia might be
different from the relatively acute pathogenesis of pancreatic
cancer cachexia, which could inﬂuence the way patients
respond on feeding.6,33
Another reason for the different protein kinetics found in
the studies referred to above is that of all solid cancers, pan-
creatic cancers are strongly related to a pro-inﬂammatory
state.6,7 In recent years, it has become evident that any
rapidly proliferating tumour is associated with severe
Figure 4 Net protein balance expressed as net phenylalanine balance.
Dots represent individual patients *P< 0.05.
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inﬂammatory activity in the tumour itself, in surrounding tis-
sues, and systemically, which stimulates cancer cell prolifera-
tion. This leads to acute phase protein synthesis, proliferation
of leukocytes, cancer cells, and synthesis of extracellular
matrix which all contribute to increasing protein and DNA
synthesis.9,11–13 This may partly explain the increase in basal
protein synthesis in the present study.
The fact that net protein balance during feeding was simi-
lar in both groups despite the lack of increase in protein
synthesis in cachectic patients indicates that protein conser-
vation is regulated differently in cachexia. While control
patients respond with both a decrease in protein breakdown
and an increase in protein synthesis, cachectic patients seem
only to decrease protein breakdown to preserve a positive
net balance. An explanation for the lack of protein synthesis
is that cachectic patients might have a higher anabolic thresh-
old. This is also seen in the healthy elderly. Ingestion of a
large bolus (35 g) of whey protein generates a higher whole
body anabolic response and muscle protein synthesis than a
smaller bolus (10 or 20 g).34 Thus, a single protein bolus might
be more effective than sip feeding (which is comparable to
continuous feeding). Moreover, studies using TPN indicate
that a high infusion rate or a high content of branched chain
amino acids stimulates whole body protein synthesis in
cachectic cancer patients while standard TPN infusion does
not.35,36 Clinical application will be difﬁcult, however. Satiety
effects of protein might be different in cachectic cancer
patients, most patients suffer from anorexia,5,7,37 and dietary
patterns and food preference vary greatly among cachectic
cancer patients.38 Therefore, individualized dietary care
might be needed for adequate nutritional support in cancer
cachexia.
The current study has some limitations. We used bioelectri-
cal impedance measurements for assessment of body compo-
sition. This method can underestimate the fat free mass
compared with computed tomography or dual-energy X-ray
absorptiometry analyses in surgical and oncologic patients
because of ﬂuid shifts.39,40 However, since our patients did
not show any signs of oedema, ascites, or dehydration
(see urea levels in Table 2), underestimation is likely to be
a minor issue. Another issue of the current study is that
some patients in the cachexia groups consumed less sip
feed than the control patients during the last 2 h of the
study protocol. This might result in an underestimation of
the phenylalanine rate of appearance and protein break-
down measurements. However, the difference was small
(and non-signiﬁcant) and did not inﬂuence the amino acid
enrichments (see Figure 1). We are therefore conﬁdent that
even though there may be some underestimation, the effect
of the lower sip feed intake is too small to change the con-
clusions of this study.
In conclusion, this study shows that cachectic pancreatic
cancer patients have a higher basal protein turnover, which
is positively correlated with CRP levels. Both cachectic
patients and controls are able to achieve a comparable pos-
itive net balance during feeding, suggesting that anabolic
resistance may be less of an issue in cachectic patients than
previously thought. However, in cachectic patients, this is
only achieved by reduced protein breakdown, whereas in
controls, both protein breakdown and protein synthesis are
modulated. Impaired nutritional stimulation of protein
synthesis in pancreatic cancer cachexia should be a topic in
future studies to develop more effective nutritional
interventions.
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